Friday, 16 October 2026European Markets

Coca-ColaEuropacif And INTERPARFUMS Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - coca-colaeuropacif (ccep.as) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
coca-colaeuropacif (ccep.as) €58.90 3.02% 21.88%
interparfums (itp.pa) €60.80 1.83% 21.46%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. coca-colaeuropacif (ccep.as)

3.02% forward dividend yield and 21.88% return on equity

coca-cola europacific partners plc, together with its subsidiaries, produces, distributes, and sells a range of non-alcoholic ready to drink beverages. it offers flavours, mixers, and energy drinks; soft drinks, waters, enhanced water, and isotonic drinks; and ready-to-drink tea and coffee, juices, and other drinks. the company provides its products under the coca-cola, diet coke, coca-cola zero sugar, fanta, sprite, monster energy, coca-cola energy, relentless, nalu, urge, burn, kuli, reign, powerade, appletiser, schweppes, finley, mezzo mix, royal bliss, lift, vio schorle, coca-cola signature mixers, nordic mist, smartwater, chaudfontaine, aquarius, vilas del turbon, bonaqua, apollinaris, krystal, honest, costa coffee, fuzetea, chaqwa, nestea, capri-sun, oasis, minute maid, mer, and tropico brands. in addition, it engages in the bottling and other operations. the company was formerly known as coca-cola european partners plc and changed its name to coca-cola europacific partners plc in may 2021. coca-cola europacific partners plc was founded in 1904 and is based in uxbridge, the united kingdom.

earnings per share

as for profitability, coca-colaeuropacif has a trailing twelve months eps of €3.69.

pe ratio

coca-colaeuropacif has a trailing twelve months price to earnings ratio of 15.96. meaning, the purchaser of the share is investing €15.96 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.88%.

more news about coca-colaeuropacif.

2. interparfums (itp.pa)

1.83% forward dividend yield and 21.46% return on equity

interparfums sa designs, manufactures, and distributes perfumes through license agreements with ready-to-wear, jewelry, or accessories houses in france and internationally. the company operates through perfumes and fashion segments. it serves customers under the boucheron, coach, jimmy choo, karl lagerfeld, kate spade, lanvin, montblanc, moncler, rochas, s.t. dupont, van cleef & arpels, and other brand names. the company distributes its products through wholly owned distribution subsidiaries or joint ventures, independent companies, subsidiaries of luxury good corporations, and duty-free operators. interparfums sa was founded in 1982 and is headquartered in paris, france. interparfums sa is a subsidiary of interparfums holding sa.

earnings per share

as for profitability, interparfums has a trailing twelve months eps of €1.51.

pe ratio

interparfums has a trailing twelve months price to earnings ratio of 40.26. meaning, the purchaser of the share is investing €40.26 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.46%.

more news about interparfums.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com